QSI,ORMP Stock Price and Quote

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.07
Percentage change -5.26	%

Peers: PACB BNGO BIO ILMN TWST CDNA NTRA TMO EXAS NTLA

| Held by: ARKG IWM VTI VXF IWN VTWO VFMO IWC VTWV RSSL

Index	RUT	P/E	-	EPS (ttm)	-0.70	Insider Own	26.83%	Shs Outstand	146.95M	Perf Week	0.00%
Market Cap	230.76M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	-6.74%	Shs Float	134.01M	Perf Month	2.44%
Income	-101.01M	PEG	-	EPS next Q	-0.15	Inst Own	26.26%	Short Float	17.11%	Perf Quarter	-38.24%
Sales	3.06M	P/S	75.41	EPS this Y	17.84%	Inst Trans	8.60%	Short Ratio	3.73	Perf Half Y	48.60%
Book/sh	1.29	P/B	0.98	EPS next Y	7.43%	ROA	-36.99%	Short Interest	22.92M	Perf Year	-29.21%
Cash/sh	1.14	P/C	1.10	EPS next 5Y	17.64%	ROE	-41.48%	52W Range	0.61 - 5.77	Perf YTD	-53.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	43.26%	ROI	-44.96%	52W High	-78.16%	Beta	2.76
Dividend TTM	-	Quick Ratio	11.76	Sales past 5Y	45.66%	Gross Margin	-98.10%	52W Low	105.85%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	11.99	EPS Y/Y TTM	-3.67%	Oper. Margin	-3476.88%	RSI (14)	51.74	Volatility	6.75% 6.38%
Employees	149	Debt/Eq	0.06	Sales Y/Y TTM	182.62%	Profit Margin	-3303.04%	Recom	1.67	Target Price	3.38
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-45.41%	Payout	-	Rel Volume	0.59	Prev Close	1.33
Sales Surprise	-2.76%	EPS Surprise	-27.64%	Sales Q/Q	198.00%	Earnings	May 15 AMC	Avg Volume	6.14M	Price	1.26
SMA20	5.04%	SMA50	-0.22%	SMA200	-6.27%	Trades		Volume	3,608,029	Change	-5.26%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-07-25	Initiated	Alliance Global Partners	Buy	$3.75
Dec-08-23	Initiated	H.C. Wainwright	Buy	$3
Sep-25-23	Downgrade	Canaccord Genuity	Buy → Hold	$3.50 → $2
Oct-20-21	Initiated	Canaccord Genuity	Buy	$13

May-07-25 06:40PM	Silvaco Group, Inc. (SVCO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +10.83%
Apr-24-25 08:00AM	Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025 (Business Wire)
Mar-26-25 08:00AM	Quantum-Si Begins Shipping Platinum Pro, Advancing Accessibility in Next-Gen Protein Sequencing (Business Wire)
Mar-24-25 06:01AM	Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research (Business Wire)
Mar-20-25 08:00AM	Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research (Business Wire) -9.32%
11:09AM	Loading…
Mar-17-25 11:09AM	Quantum computing, Affirm, Netflix upgrade: Market Minute (Yahoo Finance Video) +21.32%
Mar-13-25 04:05PM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.00% +19.30%
Mar-03-25 04:05PM	Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire) -5.80% +6.15%
Feb-18-25 04:05PM	Quantum-Sis Customers and Researchers to Showcase Next-Generation Protein Sequencing at AGBT 2025 (Business Wire)
Feb-13-25 08:00AM	Quantum-Si and Researchers to Showcase Next-Generation Protein Sequencing at US HUPO 2025 (Business Wire)
Feb-12-25 08:00AM	Quantum-Si to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 (Business Wire)
Feb-11-25 08:00AM	Preprint from Northwestern University Highlights Complementary Proteomic Analysis of Interleukin-6 Using Next-Generation Protein Sequencing and Mass Spectrometry (Business Wire)
Feb-04-25 08:00AM	Quantum-Si Establishes Scientific Advisory Board to Shape Next-Generation Proteomic Technologies (Business Wire) +6.04%
Jan-28-25 08:00AM	Quantum-Si and IDEX Health & Science to Partner on Optics Module for Proteus Instrument (Business Wire) -5.88%
Jan-20-25 08:00AM	Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK (Business Wire)
08:05AM	Loading…
Jan-18-25 08:05AM	Quantum-Si announces inducement grants under Nasdaq listing rule (TipRanks)
Jan-17-25 08:00AM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -11.81%
Jan-13-25 08:00AM	Quantum-Si Launches Platinum Pro: The End-to-End Solution for Deeper Insights in Proteomics (Business Wire) -27.03%
Jan-08-25 08:00AM	Quantum-Sis New Preprint Showcases Protein Barcoding as a Powerful Tool for Transforming Proteomics (Business Wire) -24.46%
Jan-03-25 04:06PM	Quantum-Si Incorporated Announces Pricing of $50 Million Registered Direct Offering of Common Stock (Business Wire)
Dec-20-24 08:00AM	Quantum-Si's New Preprint Showcases Advances in Protein Variant Detection using ProteoVue Software with Next-Generation Protein Sequencing (Business Wire)
Dec-18-24 08:00AM	Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.57%
Dec-12-24 05:00AM	Quantum-Si Expands International Distribution Network (Business Wire) -5.73%
Dec-04-24 08:30AM	Quantum-Si Launches Platinum New Library Prep Kit, Expanding Access to Next-Generation Protein Sequencing (Business Wire) +10.71%
Dec-03-24 08:30AM	Quantum-Si Introduces Protein Barcoding Kit for Multiplexed Protein Screening (Business Wire)
Nov-21-24 06:00AM	Quantum-Si Highlights Major Technical Advances, Next-Generation Platform Architecture and New Proteomic Applications at Investor and Analyst Event (Business Wire) -12.95%
Nov-20-24 07:30AM	Avantor to Distribute Quantum-Sis Next-Generation Protein Sequencing Technology (Business Wire) +119.59%
07:00AM	Quantum-Si to Develop Acceleration Platform and Advance Core Technologies in Collaboration with NVIDIA (Business Wire)
06:30AM	Quantum-Si Expands Collaboration with SkyWater to Develop New Chip Production Process Critical for Groundbreaking New Proteomics Platform (Business Wire)
06:00AM	Quantum-Si and Planet Innovation to Partner on Proteus (Business Wire)
04:01PM	Loading…
Nov-18-24 04:01PM	Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.00%
Nov-13-24 06:00AM	Quantum-Si Honored with Frost & Sullivan's 2024 Technology Innovation Leadership Award for Next-Generation Protein Sequencing (Business Wire)
Nov-12-24 07:30AM	Quantum-Si Reports Third Quarter 2024 Financial Results (Business Wire) -22.43%
Nov-07-24 04:01PM	University of Virginia Researchers Publish New Study on Tropomyosin Proteoforms Showcasing Quantum-Sis Next-Gen Protein Sequencer Platinum (Business Wire)
Nov-05-24 09:00AM	Quantum-Si to Participate in Upcoming Investment Conferences (Business Wire) +11.92%
Oct-31-24 03:35PM	Quantum-Si to Host Investor & Analyst Event in New York City on November 20th, 2024 (Business Wire) -5.27%
Oct-30-24 06:00AM	Quantum-Si to Present at the 2024 American Society of Human Genetics Annual Meeting (Business Wire)
Oct-23-24 06:00AM	Quantum-Si to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (Business Wire)
Oct-17-24 05:21PM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-10-24 06:00AM	Renowned Proteomic Researchers to Present Quantum-Si Data at World HUPO 2024 (Business Wire)
Sep-24-24 06:00AM	Northwestern Proteomics Center of Excellence Partners with Quantum-Si for Webinar on Advancing Proteoform Analysis with Top-Down Mass Spectrometry and Single-Molecule Sequencing (Business Wire)
Sep-19-24 06:00AM	Quantum-Si to Host Investor & Analyst Event in New York City on November 20th, 2024 (Business Wire) +6.00%
Sep-04-24 06:00AM	Liberate Bio Integrates Quantum-Si's Next-Generation Protein Sequencing Platform to Enhance Gene Therapy Development (Business Wire)
Aug-27-24 06:01PM	CORRECTING and REPLACING Quantum-Si Announces New Executive Team Members to Accelerate the Evolution of the Company into a Leading Proteomic Tool Provider (Business Wire)
04:30PM	Quantum-Si Announces New Executive Team Members to Accelerate the Evolution of the Company into a Leading Proteomic Tool Provider (Business Wire)
Aug-26-24 06:00AM	Quantum-Si to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) -5.94%
Aug-07-24 04:02PM	Quantum-Si Reports Second Quarter 2024 Financial Results (Business Wire) -5.91%
Jul-30-24 04:05PM	Quantum-Si to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-17-24 04:05PM	Quantum-Si to Report Second Quarter 2024 Financial Results on August 7, 2024 (Business Wire) -6.03%
Jul-09-24 03:56PM	3 Super-Cheap Penny Stocks for the Ultimate Speculator (InvestorPlace)
Jun-10-24 09:00AM	Quantum-Si Announces Presentation on the Use of Next-Generation Protein Sequencing to Detect Disease-Relevant Proteoforms at the Festival of Genomics and Biodata (Business Wire)
May-31-24 08:00AM	Quantum-Si Announces Presentations at ASMS and ESHG (Business Wire)
May-30-24 04:05PM	Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors (Business Wire)
May-09-24 04:01PM	Quantum-Si Reports First Quarter 2024 Financial Results (Business Wire) -7.10%
Apr-30-24 08:30AM	Quantum-Si Announces Upgrades to Analysis Software that will Provide Customers with Higher Data Output and Precision and Shorter Processing Time (Business Wire)
Apr-18-24 04:05PM	Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Mar-21-24 04:05PM	Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors (Business Wire) -5.79%
Mar-07-24 12:01PM	Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing on Platinum at US HUPO Conference (Business Wire) +29.81%
Feb-29-24 04:05PM	Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +10.78%
Feb-27-24 08:30AM	Renowned Scientist Christopher Mason, Ph.D. and Quantum-Si Collaborate for Exclusive GenomeWeb Webinar (Business Wire) +5.36%
Feb-09-24 08:00AM	Quantum-Si to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 (Business Wire) +6.94%
Feb-05-24 08:00AM	Quantum-Si Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing Platform (Business Wire)
Jan-18-24 08:30AM	Quantum-Si Introduces Worlds First Next-Generation Protein Sequencer in Japan with Addition of New Distributor (Business Wire)
Dec-12-23 08:30AM	Quantum-Si Expands Global Reach with Addition of New Distributor (Business Wire)
Nov-15-23 08:30AM	Quantum-Si Adds Distributor ELTA 90 as Demand for Platinum Grows (Business Wire)
Nov-11-23 09:18AM	Quantum-Si incorporated (NASDAQ:QSI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Quantum-Si Reports Third Quarter 2023 Financial Results (Business Wire) +7.26% +6.77%
Nov-08-23 08:15AM	Quantum-Si Honored as Proteomics Company of the Year by the BioTech Breakthrough Awards (Business Wire) -6.06%
Nov-01-23 08:30AM	Quantum-Si to Participate at Two Upcoming Investor Conferences (Business Wire)
Oct-31-23 08:00AM	Quantum-Si Presents its Vision to Transform Genomics and Proteomics Research at ASHG 2023 (Business Wire)
Oct-17-23 08:30AM	Quantum-Si to Report Third Quarter 2023 Financial Results on November 9, 2023 (Business Wire)
Oct-05-23 06:36PM	CORRECTING AND REPLACING Quantum-Si Hosts Webinar on Advances in Protein Identification and Characterization (Business Wire)
08:00AM	Quantum-Si Hosts Webinar on Advances in Protein Identification and Characterization (Business Wire)
Oct-03-23 08:00AM	Quantum-Si to Present at The Festival of Genomics & Biodata 2023 in Boston, Massachusetts (Business Wire)
Sep-21-23 08:00AM	Quantum-Si Appoints Biotech Executive and Entrepreneur, Amir Jafri, to its Board of Directors (Business Wire)
Aug-22-23 07:05AM	Quantum-Sis Platinum Next-Generation Protein Sequencing Instrument Wins Honorable Mention in Fast Companys 2023 Innovation by Design Awards (Business Wire)
Aug-16-23 04:00PM	Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-14-23 06:02PM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.73%
Aug-07-23 08:00AM	Quantum-Si Reports Second Quarter 2023 Financial Results (Business Wire) -32.15%
Jul-26-23 08:00AM	Quantum-Si to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-18-23 04:00PM	Quantum-Si to Report Second Quarter 2023 Financial Results on August 7, 2023 (Business Wire) +9.57%
Jun-21-23 08:00AM	Quantum-Si Announces the Appointment of Industry Veteran Johan Denecke as Senior Vice President of Operations (Business Wire)
Jun-07-23 08:00AM	Quantum-Si Debuts New Headquarters in Branford, Connecticut (Business Wire)
May-25-23 08:00AM	Quantum-Si to Participate in the Jefferies Healthcare Conference (Business Wire) -5.99%
May-22-23 08:00AM	Quantum-Si Appoints Life Sciences and Diagnostics Industry Leader Jack Kenny to its Board of Directors (Business Wire) +15.13%
May-15-23 08:00AM	Scott Mendel Elected to Quantum-Si Board of Directors (Business Wire)
May-11-23 04:00PM	Quantum-Si Reports First Quarter 2023 Financial Results (Business Wire) -5.52% -8.44%
May-02-23 08:00AM	Quantum-Si Announces the Appointment of Jeff Keyes as Chief Financial Officer (Business Wire)
Apr-24-23 08:00AM	Quantum-Si Bolsters Executive Leadership Team with Four Key Appointments (Business Wire)
Apr-20-23 08:00AM	Quantum-Si to Report First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-14-23 08:00AM	Quantum-Si To Present Poster on Single-Molecule Method for Detection of Arginine Post-Translational Modifications at the AACR Annual Meeting 2023 (Business Wire)
Mar-24-23 08:00AM	Quantum-Si to Participate in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference (Business Wire)
Mar-06-23 08:00AM	Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results (Business Wire) -12.96%
Feb-17-23 08:00AM	Quantum-Si to Participate in the 43rd Annual Cowen Health Care Conference (Business Wire)
Feb-13-23 04:00PM	Quantum-Si to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023 (Business Wire)
Jan-09-23 08:00AM	Quantum-Si Begins Commercial Shipments of the PlatinumTM Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire) +8.72%
08:00AM	Quantum-Si and Biovista Partner to Provide AI-Driven Deep Proteomics Insights from the Platinum Next-Generation Protein Sequence Platform Output (Business Wire)
08:00AM	Quantum-Si and Aviva Systems Biology Partner to Co-Develop Sample Preparation Kits for Protein Sequencing (Business Wire)
Dec-22-22 04:05PM	Quantum-Si to Participate in the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-20-22 08:00AM	Quantum-Si Announces Commercial Availability of PlatinumTM, the Worlds First Next-Generation Single-Molecule Protein Sequencing Platform (Business Wire)

Quantum-Si, Inc. is a life sciences company focused on revolutionizing the growing field of proteomics. It engages in the development of a proprietary universal single-molecule detection platform to enable Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins in a massively parallel fashion. Its platform includes platinum NGPS instrument, platinum analysis software, and consumable kits for platinum instrument. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Branford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hawkins Jeffrey Alan	President & CEO	Mar 21 '25	Sale	1.39	23,707	32,846	2,646,716	Mar 24 06:48 PM
LaPointe Christian	General Counsel & Corp. Secr.	Mar 21 '25	Sale	1.39	4,896	6,783	983,480	Mar 24 06:42 PM
Keyes Jeffry R.	Chief Financial Officer	Mar 21 '25	Sale	1.39	8,626	11,951	1,188,194	Mar 24 06:34 PM
Vieceli John S.	Chief Product Officer	Mar 21 '25	Sale	1.39	4,317	5,981	864,509	Mar 24 06:11 PM
ROTHBERG JONATHAN M	Director	Dec 27 '24	Sale	3.34	3,506,267	11,716,735	1,250,000	Dec 31 08:27 PM
ROTHBERG JONATHAN M	Director	Dec 27 '24	Proposed Sale	3.34	3,506,267	11,716,541		Dec 27 06:18 PM
Vieceli John S.	Chief Product Officer	Dec 23 '24	Sale	1.29	4,306	5,570	160,493	Dec 26 06:21 PM
Vieceli John S.	Chief Product Officer	Sep 23 '24	Sale	0.95	2,192	2,073	166,916	Sep 25 04:24 PM
Vieceli John S.	Chief Product Officer	Sep 24 '24	Sale	0.93	2,117	1,970	164,799	Sep 25 04:24 PM
Hawkins Jeffrey Alan	President & CEO	Aug 09 '24	Buy	0.85	25,000	21,272	1,003,757	Aug 13 06:01 AM
LaPointe Christian	General Counsel & Corp. Secr.	Aug 09 '24	Buy	0.86	25,000	21,610	571,710	Aug 13 06:01 AM
Keyes Jeffry R.	Chief Financial Officer	Aug 09 '24	Buy	0.87	50,000	43,465	446,820	Aug 13 06:01 AM
Kummeth Charles R.	Director	Aug 09 '24	Buy	0.87	138,900	120,926	323,900	Aug 13 06:01 AM
Kummeth Charles R.	Director	Aug 12 '24	Buy	0.89	31,100	27,533	355,000	Aug 13 06:01 AM
Johnston Grace	Chief Commercial Officer	Jun 21 '24	Sale	1.21	4,359	5,262	299,109	Jun 25 07:18 PM
Johnston Grace	Chief Commercial Officer	Jun 24 '24	Sale	1.20	3,169	3,790	295,940	Jun 25 07:18 PM

Dollar change -0.04
Percentage change -1.75	%

ORMP Oramed Pharmaceuticals, Inc daily Stock Chart

Peers: MNKD VTVT LGND TNDM XERS NVAX AQST CAPR RIGL

| Held by: IWC SPDW DFAC DFAT AVSC GWX DFAS DCOR AVUS DFUS

Index	-	P/E	-	EPS (ttm)	-0.48	Insider Own	19.77%	Shs Outstand	39.92M	Perf Week	-3.02%
Market Cap	91.91M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	32.77M	Perf Month	6.13%
Income	-19.06M	PEG	-	EPS next Q	-0.01	Inst Own	19.98%	Short Float	2.16%	Perf Quarter	3.69%
Sales	0.00M	P/S	-	EPS this Y	85.42%	Inst Trans	13.27%	Short Ratio	3.09	Perf Half Y	-4.26%
Book/sh	3.66	P/B	0.61	EPS next Y	-	ROA	-10.14%	Short Interest	0.71M	Perf Year	-6.25%
Cash/sh	3.47	P/C	0.65	EPS next 5Y	-	ROE	-12.29%	52W Range	1.82 - 3.09	Perf YTD	-7.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.71%	ROI	-13.02%	52W High	-27.18%	Beta	1.67
Dividend TTM	-	Quick Ratio	25.19	Sales past 5Y	-75.21%	Gross Margin	-	52W Low	23.63%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	25.19	EPS Y/Y TTM	-446.08%	Oper. Margin	-	RSI (14)	49.30	Volatility	4.83% 4.25%
Employees	13	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	3.00	Target Price	3.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-177.26%	Payout	-	Rel Volume	0.25	Prev Close	2.29
Sales Surprise	-	EPS Surprise	-1150.00%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	229.53K	Price	2.25
SMA20	-0.49%	SMA50	-0.90%	SMA200	-3.85%	Trades		Volume	57,635	Change	-1.75%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-12-23	Downgrade	Canaccord Genuity	Buy → Hold	$30 → $3
Feb-18-22	Initiated	Cantor Fitzgerald	Overweight	$20
Apr-20-21	Initiated	Canaccord Genuity	Buy	$27
Feb-09-21	Initiated	National Securities	Buy
Dec-03-20	Initiated	Alliance Global Partners	Buy	$11
Mar-11-20	Initiated	Aegis Capital	Buy	$5.50
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$7
Dec-11-17	Resumed	B. Riley FBR, Inc.	Buy	$20
May-26-16	Reiterated	FBR Capital	Outperform	$15 → $20
Dec-01-15	Reiterated	H.C. Wainwright	Buy	$24 → $25
Nov-19-15	Initiated	FBR Capital	Outperform	$15
Apr-13-15	Resumed	MLV & Co	Buy	$27 → $30
Jan-30-14	Reiterated	Aegis Capital	Buy	$30 → $35
Jan-08-14	Reiterated	Aegis Capital	Buy	$25 → $30
Jan-08-14	Initiated	MLV & Co	Buy	$27
Dec-03-13	Initiated	Aegis Capital	Buy	$25

Show Previous Ratings

May-09-25 06:18PM	WEX, Acelyrin, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-28-25 09:00AM	Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical (PR Newswire)
09:00AM	Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals (GlobeNewswire)
Mar-04-25 09:00AM	Oramed Pharmaceuticals Issues Letter to Shareholders (PR Newswire) +7.00%
Feb-11-25 09:15AM	Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin (PR Newswire) +19.82%
09:00AM	Loading…
Dec-16-24 09:00AM	Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Oct-07-24 10:00AM	Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt (PR Newswire)
Aug-15-24 05:12AM	Oramed: Q2 Earnings Snapshot (Associated Press Finance)
Jul-08-24 03:07PM	3 Micro-Cap Moonshots for Fearless Investors (InvestorPlace)
Jun-26-24 09:05AM	Oramed Letter to Shareholders (PR Newswire) +14.73%
09:00AM	Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock (PR Newswire)
May-09-24 11:53PM	ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
06:51PM	Oramed: Q1 Earnings Snapshot (Associated Press Finance)
Mar-19-24 09:00AM	Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Mar-07-24 10:53AM	ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
08:30AM	Loading…
Feb-20-24 08:30AM	Oramed Letter to Shareholders (PR Newswire)
Nov-10-23 05:03AM	Oramed: Q3 Earnings Snapshot (Associated Press Finance)
Oct-24-23 08:30AM	PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization (PR Newswire)
Oct-05-23 10:13AM	ORMP: Distribution Deals, JVs in Anticipation of Commercializing ORMD-0801 (Zacks)
Sep-22-23 11:38AM	Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company (PR Newswire)
Sep-21-23 06:11PM	Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company (PR Newswire)
04:05PM	Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc. (GlobeNewswire)
Sep-13-23 09:00AM	Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder (GlobeNewswire) -5.56%
Aug-02-23 07:45AM	Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally (PR Newswire)
Jun-20-23 07:55AM	Oramed to Present at the 83rd American Diabetes Association Conference (PR Newswire)
Jun-17-23 09:54AM	Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-30-23 11:06AM	ORMP: Advancing Development Efforts in China (Zacks Small Cap Research)
May-18-23 07:55AM	Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit (PR Newswire) +13.22%
May-15-23 09:05AM	Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China (PR Newswire) +10.60%
May-12-23 01:03PM	Oramed: Q1 Earnings Snapshot (AP Finance)
10:51AM	Loading…
May-02-23 10:51AM	Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company (Bloomberg) +6.53%
May-01-23 04:45PM	Oramed Appoints Ben Shapiro to its Board of Directors (PR Newswire) +7.93%
Mar-27-23 06:57AM	The past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable (Simply Wall St.)
Feb-09-23 07:55AM	Oramed Pharmaceuticals Issues Shareholder Update (PR Newswire) +5.77%
Jan-25-23 08:05AM	ORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin Efforts (Zacks Small Cap Research)
Jan-12-23 12:30PM	Oramed Pharmaceuticals Stock Plummets After Insulin Test Results (The Wall Street Journal) -76.46%
11:50AM	Why Oramed Pharmaceuticals Stock Is Crashing Today (Motley Fool)
08:02AM	Orameds oral insulin pill fails; stock is down 72% (MarketWatch)
06:19AM	Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study (Benzinga)
Jan-11-23 08:00PM	Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes (PR Newswire) +5.78%
Jan-08-23 07:38AM	Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation (Simply Wall St.)
Jan-04-23 07:55AM	Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes (PR Newswire)
Dec-21-22 08:25AM	Oramed Letter to Shareholders (PR Newswire) +14.25%
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-29-22 08:40AM	Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism (PR Newswire)
Nov-21-22 10:45AM	ORMP: Data from NASH Phase 2 Study Positive Takeaways (Zacks Small Cap Research)
Nov-17-22 01:12PM	Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study (Benzinga)
12:25PM	Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH (PR Newswire)
Nov-16-22 05:06AM	Oramed Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) -8.56%
Nov-14-22 07:55AM	Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea (PR Newswire)
Nov-10-22 04:30PM	Oramed Reports Third Quarter 2022 Financial Results (PR Newswire) +5.96% +14.74%
Nov-09-22 08:40AM	Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH (PR Newswire) -6.19%
Oct-17-22 08:07AM	Oramed Pharmaceuticals (NASDAQ:ORMP) shareholders have earned a 27% CAGR over the last three years (Simply Wall St.) +7.69%
Oct-07-22 11:06AM	Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study (Benzinga) -7.19%
08:40AM	Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine (PR Newswire)
Sep-13-22 11:59AM	Oramed Oral Insulin Shows Evidence For NASH Treatment (Benzinga)
08:40AM	Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate (PR Newswire)
Sep-06-22 07:55AM	Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire) -12.36%
Aug-25-22 09:15AM	ORMP: Upcoming data from ORA-D-013-1 & NASH studies could be catalysts (Zacks Small Cap Research)
Aug-01-22 07:40AM	We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-26-22 07:55AM	Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial (PR Newswire)
Jul-12-22 02:22PM	Why Oramed Pharmaceuticals Stock Is On Fire Today (Motley Fool)
Jul-11-22 07:55AM	Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference (PR Newswire) +5.61%
Jul-08-22 05:56PM	Why Oramed Pharmaceuticals Stock Rocketed Higher Today (Motley Fool) +44.37%
Jul-07-22 07:55AM	Oramed Letter to Shareholders (PR Newswire) +12.70%
Jun-01-22 07:55AM	Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board (PR Newswire) -5.40%
May-24-22 08:10AM	Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes (PR Newswire) -5.23%
May-18-22 07:55AM	Oramed to Present at H.C. Wainwright Global Investment Conference (PR Newswire) -13.42%
May-10-22 07:12AM	Shareholders in Oramed Pharmaceuticals (NASDAQ:ORMP) have lost 58%, as stock drops 22% this past week (Simply Wall St.) -6.12%
May-03-22 08:10AM	Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1 (PR Newswire)
Apr-27-22 08:10AM	ORMP: Broadening IP Protection, Positive Physician Indicators & Studies Advancing (Zacks Small Cap Research)
Apr-05-22 08:25AM	Oramed Granted NASH Patent in Europe (PR Newswire)
Apr-04-22 08:25AM	Oramed Appoints Yadin Rozov to its Board of Directors (PR Newswire)
Mar-29-22 08:25AM	Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians (PR Newswire)
Mar-22-22 08:25AM	Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes (PR Newswire)
Mar-16-22 08:25AM	Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial (PR Newswire) +6.88%
Mar-10-22 08:25AM	Oramed to Present at Barclays Global Healthcare Conference (PR Newswire)
Feb-23-22 11:25AM	ORMP: Moving Multiple Candidates & Studies Forward (Zacks Small Cap Research) -6.11%
Feb-22-22 05:38AM	We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate (Simply Wall St.)
Jan-12-22 08:45AM	Oramed Issues Annual Message to Shareholders (PR Newswire)
Jan-05-22 07:30AM	Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins (PR Newswire) -8.29%
Dec-29-21 06:14AM	Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh (MarketWatch)
06:00AM	Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia (PR Newswire)
06:00AM	Israel's Oramed gets Vietnam pre-order for 10 mln COVID-19 vaccine doses (Reuters)
Dec-14-21 08:00AM	Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa (PR Newswire) -6.76%
Dec-08-21 07:30AM	Oramed Pharmaceuticals Appoints Chief Legal Officer (PR Newswire)
Nov-24-21 08:40AM	Oramed to Join MSCI USA Small Cap Index (PR Newswire)
Nov-23-21 08:25AM	Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study (PR Newswire)
Nov-18-21 07:40AM	Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America (PR Newswire)
Nov-11-21 09:25AM	Oramed to Present at H.C. Wainwright 7th Annual Israel Conference (PR Newswire)
Nov-10-21 10:19AM	ORMP: Financing Enhances Flexibility to Advance Multiple Opportunities (Zacks Small Cap Research) -6.30%
Nov-08-21 08:10AM	Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (PR Newswire) +10.88%
Nov-03-21 11:59AM	Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (PR Newswire) -12.89%
Oct-29-21 07:25AM	Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial (PR Newswire)
Sep-23-21 08:25AM	Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference (PR Newswire) +8.94%
Sep-15-21 08:10AM	Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment (PR Newswire)
Sep-09-21 08:25AM	Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-26-21 07:05AM	ORMP: Multiple Opportunities Advance; Senior Team Expands to Support Growth (Zacks Small Cap Research)
Aug-24-21 08:25AM	Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials (PR Newswire)
06:26AM	Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Will Probably Have Their Compensation Approved By Shareholders (Simply Wall St.)

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

QSI

Quantum-Si Incorporated

ORMP

Oramed Pharmaceuticals, Inc

Upgrade your FINVIZ experience